Enteric fever, encompassing both typhoid and paratyphoid fever, continues to be a significant global health concern. The management of this disease is complex due to evolving antimicrobial resistance patterns. This article aims to provide a comprehensive review of effective strategies for managing enteric fever in clinical practice.
Understanding the epidemiology of enteric fever is crucial for effective management. It predominantly affects regions with poor sanitation and limited access to clean water. Diagnosis is often challenging due to non-specific symptoms. Therefore, a high index of suspicion is needed in endemic areas or in patients with relevant travel history. Blood culture remains the gold standard for diagnosis, but newer molecular techniques are emerging as valuable diagnostic tools.
The cornerstone of enteric fever management is antimicrobial therapy. However, increasing resistance to traditional first-line drugs like chloramphenicol, ampicillin, and trimethoprim-sulfamethoxazole necessitates the use of fluoroquinolones, azithromycin, or third-generation cephalosporins. It's crucial to monitor local resistance patterns and adjust treatment accordingly.
Vaccination is an important preventive measure, especially in endemic areas and for travelers. Two vaccines are currently available: the Vi polysaccharide vaccine and the live attenuated Ty21a vaccine. Hand hygiene, safe food and water practices, and improved sanitation are also crucial in preventing enteric fever.
Managing enteric fever effectively requires a multifaceted approach that includes accurate diagnosis, appropriate antimicrobial therapy, vaccination, and preventive measures. As antimicrobial resistance continues to evolve, ongoing research and surveillance are critical to adapt treatment protocols and develop new therapeutic strategies. By integrating these strategies, healthcare professionals can significantly improve patient outcomes and reduce the global burden of enteric fever.
1.
A study on lung cancer provides additional proof of the value of screening.
2.
Enzalutamide vs Abiraterone: Which is Better for mCSPC?
3.
Is It Really Cancer? More Concerns About Accelerated Approval; Metformin and Cancer
4.
Germline Profiling May Improve Risk Stratification in t-MNs
5.
If CD19 CAR T-Cell Therapy Fails in Lymphoma, Try a CD22 Version
1.
Understanding Blood Dyscrasia: Symptoms, Causes and Treatment Options
2.
Unraveling the Mystery of Non-Caseating Granulomas: A Comprehensive Guide
3.
Case Study: Revolutionizing PNH Treatment with Eculizumab for Superior Patient Outcomes
4.
Practical Developments in Hematology in the Digital Era
5.
Advanced Pathways in Oncology for Better Care
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Navigating the Complexities of Ph Negative ALL - Part XI
2.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part II
3.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VI
4.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part V
5.
Efficient Management of First line ALK-rearranged NSCLC - Part III
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation